日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)

曲洛单抗治疗中重度特应性皮炎:两项为期 52 周的随机、双盲、多中心、安慰剂对照 III 期试验(ECZTRA 1 和 ECZTRA 2)的结果

Wollenberg, A; Blauvelt, A; Guttman-Yassky, E; Worm, M; Lynde, C; Lacour, J-P; Spelman, L; Katoh, N; Saeki, H; Poulin, Y; Lesiak, A; Kircik, L; Cho, S H; Herranz, P; Cork, M J; Peris, K; Steffensen, L A; Bang, B; Kuznetsova, A; Jensen, T N; Østerdal, M L; Simpson, E L

Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting

特应性湿疹试验中健康相关生活质量、长期控制和瘙痒强度的推荐核心结局指标:HOME VII 共识会议结果

Thomas, K S; Apfelbacher, C A; Chalmers, J R; Simpson, E; Spuls, P I; Gerbens, L A A; Williams, H C; Schmitt, J; Gabes, M; Howells, L; Stuart, B L; Grinich, E; Pawlitschek, T; Burton, T; Howie, L; Gadkari, A; Eckert, L; Ebata, T; Boers, M; Saeki, H; Nakahara, T; Katoh, N

Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials

度普利尤单抗治疗日本中重度特应性皮炎成年患者的疗效和安全性:三项临床试验的亚组分析

Katoh, N; Kataoka, Y; Saeki, H; Hide, M; Kabashima, K; Etoh, T; Igarashi, A; Imafuku, S; Kawashima, M; Ohtsuki, M; Fujita, H; Arima, K; Takagi, H; Chen, Z; Shumel, B; Ardeleanu, M

Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials

来自 III 期临床试验的数据表明,度普利尤单抗对特应性皮炎的改善作用在不同解剖区域均同样显著:

Blauvelt, A; Rosmarin, D; Bieber, T; Simpson, E L; Bagel, J; Worm, M; Deleuran, M; Katoh, N; Kawashima, M; Shumel, B; Chen, Z; Rossi, A B; Hultsch, T; Ardeleanu, M

Physiological maturation and drug responses of human induced pluripotent stem cell-derived cortical neuronal networks in long-term culture

人类诱导性多能干细胞衍生的皮质神经元网络在长期培养中的生理成熟和药物反应

A Odawara, H Katoh, N Matsuda, I Suzuki

Poor adherence to oral and topical medication in 3096 dermatological patients as assessed by the Morisky Medication Adherence Scale-8

使用 Morisky 药物依从性量表-8 评估 3096 名皮肤科患者口服和外用药物的依从性较差。

Furue, M; Onozuka, D; Takeuchi, S; Murota, H; Sugaya, M; Masuda, K; Hiragun, T; Kaneko, S; Saeki, H; Shintani, Y; Tsunemi, Y; Abe, S; Kobayashi, M; Kitami, Y; Tanioka, M; Imafuku, S; Abe, M; Inomata, N; Morisky, D E; Katoh, N

Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)

关于协调特应性湿疹/皮炎临床试验核心结果指标的第三次国际共识会议(HOME)的报告

Chalmers, J R; Schmitt, J; Apfelbacher, C; Dohil, M; Eichenfield, L F; Simpson, E L; Singh, J; Spuls, P; Thomas, K S; Admani, S; Aoki, V; Ardeleanu, M; Barbarot, S; Berger, T; Bergman, J N; Block, J; Borok, N; Burton, T; Chamlin, S L; Deckert, S; DeKlotz, C C; Graff, L B; Hanifin, J M; Hebert, A A; Humphreys, R; Katoh, N; Kisa, R M; Margolis, D J; Merhand, S; Minnillo, R; Mizutani, H; Nankervis, H; Ohya, Y; Rodgers, P; Schram, M E; Stalder, J F; Svensson, A; Takaoka, R; Teper, A; Tom, W L; von Kobyletzki, L; Weisshaar, E; Zelt, S; Williams, H C

Thymic stromal lymphopoietin expression is increased in the horny layer of patients with atopic dermatitis

特应性皮炎患者角质层中胸腺基质淋巴细胞生成素表达增加

Sano, Y; Masuda, K; Tamagawa-Mineoka, R; Matsunaka, H; Murakami, Y; Yamashita, R; Morita, E; Katoh, N

The role of interleukin-16 in murine contact hypersensitivity

白细胞介素-16在小鼠接触性超敏反应中的作用

Masuda, K; Katoh, N; Soga, F; Kishimoto, S

Increased levels of serum tissue inhibitor of metalloproteinase-1 but not metalloproteinase-3 in atopic dermatitis

特应性皮炎患者血清中金属蛋白酶组织抑制剂-1水平升高,但金属蛋白酶组织抑制剂-3水平未升高

Katoh, N; Hirano, S; Suehiro, M; Ikenaga, K; Yasuno, H